Evaluation of vancomycin dosing regimen in patients with acute kidney injury

Comparison of pharmacokinetic parameters and clinical outcomes of vancomycin administered in two different dosage regimens in patients with acute kidney injury

Status

Active, not recruiting

Phases

Phase 3

Study type

Observational

Source

IRCT

Registry ID

IRCT20130917014693N16

Enrollment

Registered

2023-01-26

Start date

2023-03-20

Completion date

Unknown

Last updated

2023-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute kidney injury. Acute renal failure, unspecified

Interventions

Intervention 1: Control group: patients in this group will be received Vancomycin with the dose of 15-20 mg/kg every 12 hour over 60 minute infusion as empiric or targeted therapy. Intervention 2: Int

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Receiving at least four doses of vancomycin Suffering from acute kidney injury according to KDIGO guideline while receiving vancomycin as said

Exclusion criteria

Exclusion criteria: Pregnant or breastfeeding Younger than 18 years old History of chronic kidney disease History of vancomycin allergy

Design outcomes

Primary

Measure	Time frame
Percentage of patients who reach therapeutic target of Area under the curve (AUC)/Minimum inhibitory concentration (MIC) over 400. Timepoint: First and forth day of study. Method of measurement: measuring plasma level of vancomycin with ECL Immunoassay method.	—

Secondary

Measure	Time frame
Clinical condition improvement like the rate of fever or mortality. Timepoint: daily. Method of measurement: observation.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Sahraei

Shahid Beheshti University of Medical Sciences

z.sahraei@sbmu.ac.ir+98 21 8887 3704

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026